Stock Markets June 8, 2026 08:28 AM

Shattuck Labs Shares Climb After Phase 1 Data Shows Durable DR3 Blockade

SL-325 demonstrates low immunogenicity and sustained target inhibition as company outlines Phase 2b plans for Crohn's disease

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
STTK

Shares of Shattuck Labs (STTK) rose 17% Monday after the company reported positive Phase 1 clinical trial results for SL-325, a DR3-blocking antibody. The trial, which enrolled 72 healthy volunteers across dose cohorts from 0.1 mg/kg to 30.0 mg/kg, showed low immunogenicity with 3.7% of participants developing antidrug antibodies, complete DR3 occupancy at all dose levels, and sustained inhibition of TL1A binding for more than 10 weeks and beyond three months at higher doses. SL-325 was well tolerated with no serious treatment-emergent adverse events. Shattuck plans a Phase 2b Crohn's disease trial in the third quarter of 2026 and is advancing a bispecific candidate, SL-846, toward first-in-human studies expected in the first half of 2027.

Shattuck Labs Shares Climb After Phase 1 Data Shows Durable DR3 Blockade
STTK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SL-325 Phase 1 trial in 72 healthy volunteers showed low immunogenicity with antidrug antibodies in 3.7% of participants.
  • Complete DR3 occupancy observed at all dose levels from 0.1 mg/kg; complete blockade of TL1A binding lasted more than 10 weeks and extended beyond three months at doses 1 mg/kg and higher.
  • SL-325 was well tolerated with no serious treatment-emergent adverse events; all treatment-related events were Grade 1 in 12 participants. Company to start a Phase 2b Crohn's disease trial in Q3 2026 and is advancing SL-846 toward Phase 1 in H1 2027.

Shattuck Labs, Inc. (NASDAQ:STTK) saw its stock jump 17% on Monday after releasing Phase 1 clinical data for SL-325, its monoclonal antibody designed to block the DR3 receptor involved in inflammatory and immune-mediated conditions.

The early-stage study enrolled 72 healthy volunteers distributed across multiple dose cohorts spanning 0.1 mg/kg to 30.0 mg/kg. According to the company, SL-325 produced a low immunogenicity signal, with antidrug antibodies detected in 3.7% of participants.

Key pharmacodynamic findings included full DR3 receptor occupancy at every dose level tested, beginning at 0.1 mg/kg. At doses of 1 mg/kg and above, investigators observed complete blockade of TL1A binding to DR3 that persisted for more than three months. The report also notes that complete inhibition of TL1A binding was maintained for in excess of 10 weeks across dose groups.

Safety outcomes were favorable in this Phase 1 assessment. SL-325 was well tolerated across the studied dose range with no serious treatment-emergent adverse events reported. All treatment-related adverse events were Grade 1 in severity and occurred in 12 participants. The trial data showed no evidence of DR3 agonism or of SL-325 inducing lymphocyte proliferation.

Building on these results, Shattuck Labs intends to initiate RECEPTIVE-CD1, a randomized, double-blind, placebo-controlled Phase 2b trial in patients with moderate-to-severe Crohn's disease, in the third quarter of 2026. The trial will assess two dose levels of SL-325 administered as monotherapy versus placebo and is expected to enroll approximately 174 patients across sites in the United States, Canada, and Europe.

Separately, the company disclosed progress on its lead bispecific candidate, SL-846, which targets both DR3 and the IL-23 receptor. SL-846 is currently undergoing IND-enabling toxicology studies, and Shattuck expects to begin Phase 1 testing in the first half of 2027.


Implications for markets and sectors

  • Biotechnology and pharmaceutical equities, particularly small-cap clinical-stage developers, are sensitive to trial readouts such as this and were directly affected by the share movement in STTK.
  • Clinical-stage pipelines targeting immune-mediated diseases may receive renewed attention as companies and investors re-evaluate competitive positioning based on mechanism-specific data.

Further context and limitations

The information provided reflects the company's reported Phase 1 trial outcomes and its stated development timelines. The report does not include additional data beyond what was released regarding immunogenicity rates, duration of receptor blockade, safety grading, enrollment numbers, dosing ranges, or planned trial parameters.

Risks

  • Clinical development risk - outcomes in healthy volunteers do not guarantee similar safety or efficacy in patients with Crohn's disease, impacting the pharmaceutical and biotech sectors.
  • Execution and timeline risk - planned initiation of the RECEPTIVE-CD1 Phase 2b trial in Q3 2026 and SL-846 Phase 1 in H1 2027 are company projections subject to change, affecting project timelines and investor expectations.
  • Regulatory and trial enrollment risk - conducting a randomized, double-blind, placebo-controlled trial across multiple countries introduces operational and regulatory complexities that could influence the clinical program and market valuation.

More from Stock Markets

Pentagon Expands List of Firms Tied to China’s Military, Adding Alibaba, BYD and Baidu Jun 8, 2026 Goldman Forecasts World Cup Will Lift U.S. Payrolls by 40,000 in June Jun 8, 2026 At WWDC, Apple Aims to Recast Siri and Leverage Device Fleet in AI Push Jun 8, 2026 Barclays Identifies Building-Products Stocks With Buyback Headroom Jun 8, 2026 Cava Group Shares Edge Higher After Executive Purchases Stock Jun 8, 2026